Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

SALE: 200+ Cancer-related patent PDFs



 Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia patent thumbnailProstatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia
Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra.
Wavesense, Inc.


 Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer patent thumbnailProtein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
Aspects of the present disclosure include methods of producing a circulating analyte profile of a subject. The methods include contacting a blood sample from a subject with a panel of probes for specific binding to analytes, and detecting the presence or absence of binding of the analytes to probes of the panel of probes.
The Board Of Trustees Of The Leland Stanford Junior University


 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration patent thumbnailMethods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response to determine if said response is depressed. A method for restoring her2-specific cd4+ th1 immune response in a her2-positive breast cancer patient in need thereof, comprising: administering to said patient a therapeutically effective amount of a dendritic cell (“dc”) vaccine comprising autologous dcs pulsed with her2-derived mhc class ii binding peptides (“dc vaccination”) to elevate said patient's anti-her2 cd4+ th1 response, and measuring said anti-her2 th1 response of said patient pre- and post-dc vaccination to determine the amount of increase in said response..
The Trustees Of The University Of Pennsylvania


 Disposable single cell array for personalized diagnostics patent thumbnailDisposable single cell array for personalized diagnostics
Paper-based single cell arrays are provided, as well as methods of making and using the arrays. The invention provides a low cost, high-throughput platform to detect and quantify different types of dna damage at point-of-care without expensive equipment or highly trained personnel.
Northeastern University


 Methods and compositions for prognosis and treatment of cancers patent thumbnailMethods and compositions for prognosis and treatment of cancers
The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer..
Genentech, Inc.


 Next generation rna-sequencing and long non-coding rna in glioblastoma multiforme patent thumbnailNext generation rna-sequencing and long non-coding rna in glioblastoma multiforme
Lncrnas are emerging as important oncogenic drivers in many cancers, but comprehensive, agnostic studies to identify key lncrnas involved in gbm are lacking. Described herein are new lncrna involved in gliomagenesis and prognosis, elucidating the biological functions of these relatively unknown biological actors and opening new therapeutic avenues for therapeutic development..
University Of Southern California


 Detection and treatment of disease exhibiting disease cell heterogeneity and  communicating test results patent thumbnailDetection and treatment of disease exhibiting disease cell heterogeneity and communicating test results
This disclosure provides, among other things, methods for generating and applying therapeutic interventions. The methods involve, for example, (a) sequencing polynucleotides from cancer cells from a subject; (b) identifying and quantifying somatic mutations in the polynucleotides; (c) developing a profile of tumor heterogeneity in the subject indicating the presence and relative quantity of a plurality of the somatic mutations in the polynucleotides, wherein different relative quantities indicates tumor heterogeneity; and (d) determining a therapeutic intervention for a cancer exhibiting the tumor heterogeneity, wherein the therapeutic intervention is effective against a cancer having the profile of tumor heterogeneity determined..
Guardant Health, Inc.


 Methods and materials for treating endometrial cancer patent thumbnailMethods and materials for treating endometrial cancer
This document provides methods and materials for detecting and/or treating endometrial hyperplasia and/or endometrial cancer. For example, this document provides methods and materials for identifying a female mammal as having endometrial hyperplasia and administering a therapy (e.g., hormone therapy) to the female mammal.
Mayo Foundation For Medical Education And Research


 Active cxcr4+ immune cells and methods for their production and use patent thumbnailActive cxcr4+ immune cells and methods for their production and use
Provided herein are active cxcr4+ cd8+ t cells, active cxcr4+ type-1 cd4+ t cells and active cxcr4+ nk cells and populations of those cells, methods for making active cxcr4+ t cells and nk cells and populations of those cells, and methods for using active cxcr4+ t cells and nk cells and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.. .
University Of Pittsburgh - Of The Commonewalth System Of Higher Education


 Compositions and methods for tumor transduction patent thumbnailCompositions and methods for tumor transduction
The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.. .
Aleta Biotherapeutics Inc.


Cancer-cell-specific antibody, anticancer drug, and cancer testing method

An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (tmem-180) antibody or an antigen-binding fragment thereof.
Rin Institute Inc.

Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described..
Pharosgen

Mutations in the extracellular domain iii of epidermal growth factor receptor gene

The invention relates to new identified mutations in the epidermal growth factor receptor gene, leading to amino acidic changes which highly correlate with the resistance to a therapy regimen comprising cetuximab. The invention includes peptide sequences and primers to detect the mutations, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab.
FundaciÓ Institut Mar D'inversigacions MÈdiques (imim)

Uterine cancer treatments

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same

The invention features homo-multimers, e.g., homo-trimers, of tnfsf or tnf-like ligand muteins in which each tnfsf ligand or tnf-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring tnfsf or tnf-like ligand mutein monomer. The invention features methods of producing such tnfsf and tnf-like ligand muteins, pharmaceutical compositions containing such muteins, and methods of using such muteins in cancer immunotherapy, in treating autoimmune and neurological diseases, and in reducing or eliminating the complications and risks of rejection in organ transplantation or tissue or organ repair or regeneration..
The General Hospital Corporation

Method for preparing marmycin a and analogues thereof, and also uses thereof

The present invention relates to a method for preparing marmycin a and analogues thereof, to novel marmycin a analogues, and also to the use of these compounds as an organelle marker and in pharmacy, in particular as antibiotics, anticancer agents and antimalarials.. .
Université Pierre Et Marie Curie (paris 6)

Kinase inhibitors and related methods of use

The present disclosure is directed to compounds that may selectively inhibit death associated protein kinases (dapks) as well as pim kinases. The compounds can be used in methods of treating various disorders, including cancers..
University Of Calgary

No- and h2s- releasing compounds

This disclosure relates to compounds containing both an no-releasing moiety and an h2s-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.. .
Research Foundation Of The City University Of New York

Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase

Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress n—cor. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses tctp and methods for determining whether a compound is effective in inducing cell death..
Lixte Biotechnology, Inc.

Bioelectronic medical system for cancer treatment

A process, method, and devices thereof for the rapid destruction of cancer tumor(s) which are made up of thousands to millions of living malignant cancer cells. Such an approach seeks to kill said tumor(s) by causing apoptosis or excitotoxicity and/or osmotic-shock within a human or animal for medical treatment.
Neuro Code Tech Holdings, Llc.

Tunable ph-sensitive linker for controlled drug release

A novel acid labile linker for targeted delivery and/or controlled phosphoryl hydroxypropylglycine release of agents is introduced herein. There is further disclosed a method of developing a therapeutic or diagnostic conjugate for targeted cell-specific delivery.
Washington State University

Compounds and methods for the treatment of erb b2/neu positive diseases

Disclosed herein are anti-erb b2/neu antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat erb b2/neu positive cells in cancers are provided..
Bio-thera Solutions, Ltd., Co.

Conjugates for treating diseases caused by psma expressing cells

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by psma expressing cells, such as prostate cancer cells, using compounds capable of targeting psma expressing cells..
Endocyte, Inc.

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a pd-1 inhibitor).. .
Neotx Therapeutics Ltd.

Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies

Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with her2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-her2 antibody that is not an inhibitor of her2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-her2 antibody..
Merrimack Pharmaceuticals, Inc.

Protease-engineered cancer cell spheres as an immunotherapy to treat cancer and non-cancer diseases

Disclosed is a method of making a proteinase-engineered cancer vaccine or cancer-cell-derived spheres for treating a cancer patient, especially for cancer patients at advanced/metastatic stage. The cancer vaccine comprises dead cancer-cell-derived spheres with unbroken plasma membrane wherein the extracellular proteins and extracellular portion of membrane proteins are cleaved by proteinase digestion.

Annexin a2 as immunological target

Annexina2 (anxa2), a member of the annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. Annexina2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane annexina2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas.
The Johns Hopkins University

Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and the prognosis of survival of a patient who has a solid cancer

The invention relates to an epha2 inhibitor for the use thereof in the treatment of solid cancer treated with a trka inhibitor, and a trka inhibitor for the use thereof in the treatment of solid cancer treated with an epba2 inhibitor. The invention also relates to a method for the prognosis of survival of a patient who has a solid cancer, comprising a step of detecting the expression of trka and epha2 in a biological sample of the patient, the co-expression of trka and epha2 being associated with a poor prognosis of survival of the patient..
Inserm (institut National De La Sante Et De La Recherche Medicale)

Method for treating cancer

A method for treating a cancer by administering a therapeutically active composition for the treatment in a patient or human thereof, is disclosed. The method according to the present invention, comprises a step of administering to the human a pharmaceutical composition comprising a therapeutic amount of sodium thiosulfate (na2s2o3) along with at least one of a pharmaceutical carrier and a pharmaceutical excipient.

Fosfestrol for use in curative or palliative treatment of prostate cancer

The invention further provides an oral dosage unit comprising at least 500 mg, of fosfestrol.. .

Methods for treating cancers

Or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer.

Method for treating prostate cancer

The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of cdk8 and cdk19. In some embodiments the inhibitor inhibits cdk19.
University Of South Carolina

Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function

Disclosed herein are novel methods and compositions useful for promoting intestinal stem cell function. The methods and compositions are particularly useful for stimulating the proliferation of and/or self-renewal of intestinal stem cells, as well as for minimizing, preventing, or ameliorating cellular damage resulting from incidental or accidental exposure to radiation (e.g., cancer radiation therapy)..
Massachusetts Institute Of Technology

Priming of pancreatic tumor cells and cancer stem cells to trail-induced apoptosis

This invention relates generally to compositions and methods for treatment of pancreatic cancer. The present invention relates more particularly to use of jnk inhibition together with administration of trail to selectively suppress cancer stem cells..
Alliance Of Cardiovascular Researchers

Methods for treating brain metastasis

The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing protocadherin 7 and connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of protocadherin 7 and/or connexin 43 expression in cancer cells reduce progression of brain metastases.
Memorial Sloan-kettering Cancer Center

Prostate cancer ablation

Methods and systems for delivering electrical energy and controlled, mild hyperthermia to a prostate tissue of a patient for destruction of cancerous and/or hyperplastic tissue. A method includes positioning a plurality of electrodes in a target tissue region comprising the prostate tissue, and establishing an alternating electrical current flow through a volume of the prostate tissue to induce mild heating and destruction of cancerous cells in the volume..
Lazure Scientific, Inc.

Process for detecting prostate cancer biomarkers

A process for detecting prostate cancer biomarkers includes: subjecting seminal plasma fluid to western blot analysis; identifying a first prostate specific antigen (psa) subform in the seminal plasma fluid, based on the western blot analysis; identifying a second psa subform in the seminal plasma fluid, based on the western blot analysis; and quantifying a first amount of the first psa subform and a second amount of the second psa subform in the seminal plasma fluid to detect prostate cancer biomarkers in a subject from which the seminal plasma fluid was provided.. .
Government Of The United States, As Represented By The Secretary Of Commerce

Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and/or immunotherapy. The present invention also provides methods of using expression levels of one or more stroma signature genes as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a stroma-targeted agent..
Genentech, Inc.

Post-treatment breast cancer prognosis

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient.
The General Hospital Corporation

Target of vgsc beta-3 protein for prevention, treatment and diagnostic detection of cancers

The present application relates to inhibitors of vgscβ3 protein and use thereof and methods of using the vgscβ3 protein or an inhibitor thereof to diagnose, prevent and treat cancer, and to screen antineoplastic agents using the vgscβ3 protein or its regulatory sequences.. .
Shenyang Pharmaceutical University

Antibodies against cd73

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human cluster of differentiation 73 (cd73) with high affinity, and inhibit the activity of cd73, and optionally mediate antibody dependent cd73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Substituted pyridobenzodiazepinone-derivatives and use thereof

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures..
Bayer Pharma Aktiengesellschaft

Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors

Provided herein are compounds of the formulas: which are 90-kda heat shock protein inhibitors. Pharmaceutical compositions of the compounds are also provided.
The University Of Kansas

Photohexer compounds and pharmaceutical composition and use thereof

The present invention relates to photohexer compounds and a pharmaceutical composition and use thereof. Specifically, the present invention relates to 2(4)-(1-hexyloxy-ethyl)-6,7-bispropionate-1,3,5,8-tetramethyl-4(2)-vinylpor-phyrin and their analogues, which are water soluble, have stable properties, can be used as a photosensitizer, and are suitable for the diagnosis and treatment of malignant tumors, precancerous lesions or benign lesions.
Rainbow Pharmatech Llc

Compositions, devices and methods of use thereof for the treatment of cancers

The use of glp-1 receptor agonists, such as glucagon-like peptide-1 (glp-1) or exenatide, for the treatment of cancer is described. The glp-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the glp-1 receptor agonist for at least one month.
Intarcia Therapeutics, Inc.

Systems and methods for attracting and trapping brain cancer cells

Described herein are systems and methods for attracting and trapping cancer cells at a specific site where focal radiation and/or surgical resection and/or chemotherapeutics can eliminate them.. .
Geisinger Health System

Peptide-based methods for treating pancreatic cancer

Methods for treating pancreatic cancer via administration of small anti-inflammatory peptides. The peptides may be administered in conjunction with another therapeutic agent or therapeutic regimen..
Riptide Bioscience, Inc.

Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines

Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula i.
The Rockefeller University

Pkc delta inhibitors for use as therapeutics

The invention is directed to compounds that are specific inhibitors of pkc delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers.
Faller & Williams Technology, Llc

Edible, retrievable animal items

A flavored or unflavored pet treat-item using hemp based products and byproducts constructed to be eaten by a pet as a treat in one to two days. The outer shell of the treat-item is patterned after natural tree bark such as pine, cypress, redwood and oak.

Computer analysis of mammograms

A method of screening a population of women for breast cancer by mammography, comprising establishing a screening schedule, conducting a screening mammography on a patient in accordance with said screening schedule to obtain a mammogram image, determining whether a cancer lesion is visually observable in said mammogram image, in the event that no cancer lesion is visually observable in said mammogram image conducting a computer image analysis of the mammogram image in which no potential cancer lesion is visually observable, said method serving to determine the risk of there being such a lesion physically present or about to arise within a screening interval, said method comprising applying to the image a statistical classifier trained to score on the basis of texture features in the image that reflect such risk.. .
Biomediq A/s

Software tool for breast cancer screening

What is disclosed is a software tool which enables medical practitioners to manually or automatically analyze a thermal image of an area of breast tissue for the presence of tumorous tissue. In one embodiment, the software interface tool disclosed herein comprises a patient details object which enables the display of a patient details screen wherein a user can enter/edit patient information.
Niramai Health Analytix Pvt Ltd

Automatic segmentation of breast tissue in a thermographic image

What is disclosed is a system and method for automatically segmenting a breast from surrounding tissue in a thermal image. A thermal image of at least one breast of the patient is received.
Niramai Health Analytix Pvt Ltd

Therapeutic antibodies against ror-1 protein and methods for use of same

Therapeutic antibodies having binding specificity for ror-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ror-1 protein expressed on putative cancer cells are also provided..
The Regents Of The University Of California

Late er+ breast cancer onset assessment and treatment selection

A method for determining the likelihood of late er− breast cancer disease relapse/recurrence is disclosed. Late er+ breast cancer disease onset and/or recurrence is determined for a period of 5 to 20 years after an initial er+ breast cancer disease onset in a patient.
The University Of Notre Dame Du Lac

Micro-rna based diagnoses of ovarian and other cancers via sub-terahertz vibrational spectroscopy

Certain exemplary embodiments can provide a method, which comprises causing a determination to be made that a body fluid sample is from a patient with cancer. The determination can be made via analyzing the body fluid sample by sub-thz resonance spectroscopy with absorption determinations being made at a plurality of frequencies between 0.05 and 1.0 thz to show a presence of specific micro-rnas as cancer related molecules in the body fluid..
Vibratess, Llc

Cancer cell-trapping metal filter, cancer cell-trapping metal filter sheet, cancer cell-trapping device, and manufacturing methods therefor

According to a cancer cell-trapping metal filter 1, openings of connected through-holes 12 that are formed in a metal sheet 11 have a wave shape, and thus it is possible to extract a ctc from other components by utilizing a hole diameter on a short-side side of the openings, and it is possible to make the connected through-holes be closer to each other due to the wave shape while maintaining a ctc trapping ability. Accordingly, it is possible to further improve the opening ratio in the cancer cell-trapping metal filter 1..

Treatment of lung cancer using an anti-fucosyl-gm1 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to fucosyl-gm1.. .
Bristol-myers Squibb Company

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Combination therapy of antibodies against human csf-1r and uses thereof

The present invention relates to the combination therapy of antibodies binding to human csf-1r, characterized in binding to the (dimerization) domains d4 to d5 (seq id no: 85) of the extracellular domain of human csf-1r in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.. .
Hoffmann-la Roche Inc.

Safety for treating cancers with a glycosylated chimeric antibody to egfr

There is disclosed a chimeric cetuximab-like monoclonal antibody (cmab009 mab) having at least 80% nana glycosylation terminal sialic acid at an n-glycosylation site asn297 and a glycosylation pattern of gal-α(2,3/6)-gal. The disclosed cmab009 monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of seq id no.
Sorrento Therapeutics, Inc.

Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism

The invention provides a method for treating a cancer with a human folr1-targeting drug by increasing an expression of folate receptor α (hereinafter abbreviated to folr1) by using an antagonist for folic acid metabolism, a medicament for a cancer containing a human folr1-targeting drug for increasing an expression of folr1 by using an antagonist for folic acid metabolism and a method for enhancing a therapeutic effect of a human folr1-targeting drug by increasing an expression of folr1 in a cancer cell by using an antagonist for folic acid metabolism. For example, the invention provides a more effective therapeutic method using an antagonist for folic acid metabolism with a human folr1-targeting drug, for cancer patients in which an expression level of folr1 is low and in which an anti-tumor activity of the human folr1-targeting drug is not exhibited sufficiently or for cancer patients in which a treatment of a cancer expressing folr1 is to be further enhanced..
Kyowa Hakko Kirin Co., Ltd

Shark antibodies for cancer therapy

Sharks have been thriving for over 500 million years. Sharks evolved some of the first adaptive antibodies and developed immunoglobulin m (igm) as their primary and only class of circulating antibody.
Prolume, Ltd.

O-phenyl chalcone compounds and uses thereof

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity.
Sun Yat-sen University

Thienopyrimidine and thienopyridine compounds and methods of use thereof

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to mll1, mll2 and mll-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of mll1, mll2, mll fusion proteins, and menin..
Kura Oncology, Inc

Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer

R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.. .

Methods and compositions for inhibition of ras

Inhibitors of ras protein, methods to modulate the activity of ras protein, and methods of treatment of disorders mediated by ras protein are provided. A method for regulating activity of a k-ras, h-ras or n-ras mutant protein with a compound is described.
Araxes Pharma Llc

Pyrimidine-diamine dual hsp90/trap1 inhibitors

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical composition thereof, which are useful as dual hsp90/trap1 inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of formula (i) and their use in treating one or more cancers..
Calasia Pharmaceuticals, Inc.

18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.. .
Ruprecht-karls-universitÄt Heidelberg

Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

The present invention is directed to egfr-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide qrhkpre (seq id no: 1), hahrsws (seq id no: 2), yltmptp (seq id no: 3), typisfm (seq id no: 4), klpgwsg (seq id no: 5), iqsphff (seq id no: 6), ysipkss (seq id no: 7), shrnrprntqps (seq id no: 8), nrhkprektftd (seq id no: 9)..
The Regents Of The University Of Michigan

Compositions and methods for treatment of pre-cancerous skin lesions

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (tslp) inducer..
Washington University

Yeast-brachyury immunotherapeutic compositions

Disclosed are yeast-based immunotherapeutic compositions comprising brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of brachyury.. .
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services

Immunogenic polypeptide cocktail for the treatment of medullary thyroid carcinoma

Disclosed are immunogenic compositions that include one or more polypeptides that, when administered to a subject with adjuvant, elicit an immune response against medullary thyroid cancer. Disclosed are methods of eliciting an immune response and/or treating cancer, such as medullary thyroid carcinoma or other thyroid carcinomas..

Cholinergic antagonism as an adjunct to cancer therapy

The invention provides for methods for treating gastric cancer or colon cancer in a subject by administering a cholinergic antagonist, a botulinum toxin, a ngf inhibitior, a trk inhibitor, or performing a surgical denervation. The invention provides for inhibiting stem cells growth by administering a cholinergic antagonist, a botulinum toxin, a ngf inhibitior, a trk inhibitor, or performing a surgical denervation.
Norwegian University Of Science And Technology

Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis

Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce apoptosis selectively in tumor/cancer cells while sparing normal cells.

Method for suppressing proliferation and/or inducing apoptosis of cancer cells

It is to provide an agent for suppressing proliferation and/or inducing apoptosis of cancer cells that can be used for the treatment and chemoprophylaxis of cancer, wherein the agent is easily accessible and ingestible in daily dietary life and is prepared using a naturally-derived ingredient with reduced side effects, and a method for suppressing proliferation and/or inducing apoptosis of cancer cells in a subject in need thereof, and the like. By administering an agent for suppressing proliferation and/or inducing apoptosis of cancer cells comprising sargassum horneri or a processed product thereof to a subject in need thereof, the proliferation of cancer cells can be inhibited and apoptosis of cancer cells can be induced in the subject..
Maruhachi Muramatsu, Inc.

Antigen specific mrna cellular cancer vaccines

Disclosed are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mrna encoding said immunogenic epitopes. In one embodiment of the invention, said modified mrna encodes peptides derived from the protein survivin.
Regen Biopharma, Inc

Compositions and methods of aloe polysaccharides

The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis c..
Bespoke Bioscience, Llc

Methods of reducing mammographic breast density and/or breast cancer risk

The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman..
Havah Therapeutics Pty Ltd.

Methods of treatment of malignancies

Provided are methods and compositions for treating cancers in patients carrying an idh1 mutation or idh2 mutation.. .
Agios Pharmaceuticals, Inc.

Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (rb)-negative cancers and rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (cdk4/6) inhibitors. In one aspect, the improved treatment of select rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase i inhibitor..
G1 Therapeutics, Inc.

Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer

R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.. .

Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections

In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds..
Georgetown University

Isoflavonoid compounds and methods for the treatment of cancer

Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions..
Mei Pharma, Inc.

Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases

The present invention relates to cancer therapy by administering a specific dietary compensation. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil epa/dha and curcumin.
Oliventures, Inc.

Privacy booth for breast cancer screening

What is disclosed is an apparatus for enabling privacy for patients undergoing breast cancer screening in a non-clinical setting. One embodiment of the present apparatus comprises an enclosure in which a person can remove one or more garments to expose their breasts to a thermal camera for breast cancer screening.
Niramai Health Analytix Pvt Ltd

Hydro-jet endoscopic capsule and methods for gastric cancer screening in low resource settings

Systems and methods are provided for controlling lateral movement of a medical capsule system. A capsule housing is configured to be inserted into an anatomical structure of a patient.
Vanderbilt University

Integrated methods and systems for electrical monitoring of cancer cells stimulated by electromagnetic waves

A method for stimulating and analyzing of cancer cells, including: preparing an integrated stimulating-analyzing set-up including an array of carbon nanotubes (cnts), measuring a first electrical response from the attached cancer cells, applying an electromagnetic field on the attached cancer cells to stimulate cancer cells, measuring a second electrical response from the stimulated cancer cells, and detecting the vitality of the stimulated cancer cells by comparing the first and the second measured electrical responses.. .

Methods and devices for determining a disease state

The present invention, in some embodiments thereof, relates to methods and devices for determining a disease state in a patient. In some embodiments, human serum albumin may be analyzed for associated molecules, wherein the associated molecules are related to a disease such as cancer.
Analiza, Inc.

Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor

The present invention relates to the use of map3k8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one mek inhibitor. The invention further relates to a method for monitoring a patient affected with a high-map3k8 ovarian cancer (i.e.
Inserm (institut National De La SantÉ Et De La Recherche MÉdicale)

Methionine aminopeptidase overexpression in the peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer screening, diagnosis and prognosis

A method of screening/prognosis/diagnosis for colorectal cancer (crc) wherein methionine aminopeptidase 2 (metap2) levels are detected in a non-tumor sample such as peripheral blood, peripheral blood mononuclear cells (pbmc) or lymphocytes. Based on the metap2 levels, the individual may be selected for further testing..
Vastcon

Biomarkers of therapeutic responsiveness

The present invention relates to methods of diagnosing breast cancer in a patient, as well as methods of monitoring the progression of breast cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein..
Meso Scale Technologies, Llc.

Diagnosis and treatment of breast cancer

The present invention relates to compositions and methods for-determining a treatment course of action. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies and administration of appropriate treatments..
The Regents Of The University Of Michigan

Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene

The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer.
Genomictree, Inc.

Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene

The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer.
Genomictree, Inc.

Biomarkers for cervical cancer

The invention relates to methods, reagents and kits for detecting the susceptibility to cervical cancer. In particular, it relates to novel methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3 (cin2/3) and the use thereof for identifying a cervical cell as neoplastic or predisposed to neoplasia in an isolated sample..
Academisch Ziekenhuis Groningen

Biomarkers for cancer diagnosis and prognosis and using thereof

The present invention is related to a kit for cancer diagnosis or prognosis analysis. Mest in the present invention is a biomarker for cancer having significantly improved accuracy and reliability, especially, breast cancer and liver cancer as well as metastatic cancer.
Korea Ocean Research & Development Institute

Methods for treating cells containing fusion genes

The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: trmt11-grik2, slc45a2-amacr, mtor-tp53bp1, lrrc59-flj60017, tmem135-ccdc67 and ccnh-c5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Modulation of breast cancer growth by modulation of xbp1 activity

Described herein is a previously unknown function of xbp1 in triple-negative breast cancer (tnbc). It is shown that xbp1 is preferentially spliced and activated in tnbc, and that deletion of xbp1 significantly blocks triple negative breast tumor growth.
Cornell University

Ras exon 2 skipping for cancer treatment

There is provided ssos targeting the region of hras, kras, and hras exon 2 that harbors the activating mutations and which harbors ese activity. Moreover, there is provided ssos targeting the 3′- and 5′-splice sites.
Syddansk Universitet

Micrornas and uses thereof

Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are mirnas and mirna precursors.
Rosetta Genomics Ltd.

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a cd46, and where the antibodies specifically bind sushi domain 1 of said cd46 (cd46 cpp1)..
The Regents Of The University Of California

Human alpha-folate receptor chimeric antigen receptor

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified t cell having α-folate receptor (frα) binding domain and cd27 costimulatory domain to treat ovarian cancer.
The Trustees Of The University Of Pennsylvania

Prostate-specific membrane antigen (psma) targeting peptides

Described herein is the discovery of novel psma-specific peptides, which were identified through a novel combinatorial biopanning method. One of the novel psma-specific peptides discovered, gtiqpypfswgy (or gti) (seq id no: 2), exhibits high binding affinity and selectivity to psma and psma-positive prostate cancer cells.
The Curators Of The University Of Missouri

Anti-cancer agent and cancer cell killing method

[solution] an anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (n, n, o, o) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including gap1, synthesis, gap2, and mitosis and cytokinesis. The present disclosure is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer.

Novel small molecule anticancer agents

The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer..
University Of Florida Research Foundation

Sanguinarine analog pp2c inhibitors for cancer treatment

Sanguinarine analogs as pp2c inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.. .
Lixte Biotechnology, Inc.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Crystalline form of afatinib dimaleate

The present invention provides a crystalline form i of afatinib dimaleate, its process for preparation and pharmaceutical composition thereof, and its use in the treatment of metastatic non-small cell lung cancer.. .
Sun Pharmaceutical Industries Limited

Aminomethylene pyrazolones with therapeutic activity

Pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular, to delay, prevent or reverse metastasis in prostate cancer.. .

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Methods and compounds for restoring mutant p53 function

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants.
Pmv Pharmaceuticals, Inc.

N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof

The present invention provides a compound of general formula a, useful as potential anticancer agents against human cancer cell lines and process for the preparation thereof. [formula should be entered here] general formula a where in b selected from aryl, heteroaryl and fused heteroaryl ring r and x selected from h, hydroxy, alkyl, alkoxy, prop-2-ynyloxy, allyloxy, halo, alkylhalides, alkoxy halides, nitro, amine..
Council Of Scientific & Industrial Research

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-vegf antibody, comprising administering to the patient a therapeutically effective amount of an anti-her2 antibody while continuing said anti-vegf antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions..
Hoffmann-la Roche Inc.

Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein tryptophan2,3-di-oxygenase (tdo) or peptide fragments here of that are capable of eliciting anti-cancer immune responses.
Herlev Hospital

Universal cancer vaccine

Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing t cell epitopes that have been altered to increase immunogenicity.

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

A genetically modified mesenchymal stem cell (msc) and medical use thereof in the treatment of tumors, the msc including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.
Apceth Gmbh & Co. Kg

Aryloxy phenoxy acrylic compound having hif-1 inhibition activity, preparing same, and pharmaceutical composition containing same as an active ingredient

Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits hif-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced vegf expression by hif-1 increases..

Triazolone compounds and uses thereof

And pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of formula i, or a pharmaceutically acceptable salt thereof.

Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.. .
Genentech, Inc.

Small molecule inhibitors of n-terminus activation of the androgen receptor

Compounds having a structure of formula (a) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided.
British Columbia Cancer Agency Branch

Methods of treatment of fibrosis and cancers

The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.. .
Genfit

Use of silver(i) complexes as anticancer agents

The present invention relates to the use of silver(i) monophosphine complexes as active pharmaceutical ingredients (api's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer..
University Of Johannesburg

Method for treating skin cancer

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.. .

Targeted delivery of hydrophilic drugs

A pharmaceutical composition in form of an aqueous colloid or an aqueous suspension of particles up to a size of 100 μm comprises or consists of amphiphilic sulfonate or sulfate of a hydrophilic cancer drug having a solubility in water or aqueous body fluid of less than 0.1% by weight. Also disclosed are the particles in powderous form, methods for their production and for the production of the colloid and the courser suspension, a method of treating liver cancer, in particular solid liver cancer tumours, by administration of the pharmaceutical composition, and a method of designing a composition according to the invention..
Double Bond Pharmaceuticals Ab

Methods of diagnosing and treating cancer

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of 11βhsd1 and/or 11βhsd2 in a sample obtained from the subject, ii) comparing the expression level determined at step i) with its predetermined reference value and ii) concluding that the subject suffers from a cancer when the expression level of 11βhsd1 is lower than its predetermined reference value or when the expression level of 11βhsd2 is higher than its predetermined reference value..
UniversitÉ Paul Sabatier Toulouse Iii

Compositions for detecting cancer cells on a cellular surface

Disclosed are compositions and methods for assessing the presence of tumor cells amongst normal cells.. .
Isi Life Sciences, Inc.

Methods and compositions for prognostic and/or diagnostic subtyping of pancreatic cancer

Methods for generating a prognostic and/or subtype signature for a subject with pancreatic ductal adenocarcinoma (pdac) are provided. In some embodiments, the methods include determining expression levels for one or more genes listed in tables 2-5, 9, 10, or 11, and/or the de-s and/or de-t subset of genes in pdac cells obtained from the subject, wherein the determining provides a prognostic and/or subtype signature for the subject.
The University Of North Carolina At Chapel Hill

Method of multivariate molecule analysis

A multi-gene-based assay for analysis of the following: (a) oncogene expression; (b) dna methylation of tumor suppressor genes; (c) non-coding rna expression (microrna profiling); and (d) long non-coding rna expression in cancer samples is disclosed. The assay method and device for conducting the assay are applicable to diagnosis, prognosis, and treatment of various cancers such as lung, breast, colorectal, prostate, liver, bladder; kidney, cervix, pancreatic, gastric, brain, oral, endometrium, and ovary.
Miodx

Systems and methods of detecting solid tumor cancer

Provided herein are methods and kits for the detection of solid tumor cancers by measuring expression levels of at least one biomarker of solid tumor microenvironment potential or solid state tumor mass potential.. .
Adrastia Biotech Corporation

Microrna biomarker for the diagnosis of gastric cancer

Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one mirna having at least 90% sequence identity with an mirna as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of mirna expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the mirna may be either an mirna listed as “up-regulated” or an mirna listed as “down-regulated”.
National University Hospital (singapore) Pte Ltd

Methods for detecting cpg methylation and for diagnosing cancer

The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of hypermethylated dna. The detection of cpg methylation in marker dna is useful for the diagnosis of cancers and the invention provides improved methods for this purpose.
Epigenomics Ag

Targeted/immunomodulatory fusion proteins and methods for making same

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.. .
Biocon Limited

Dna aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer

Disclosed herein are unique single stranded dna oligonucleotide products identified as binding with high affinity and specificity to ovarian tumor cells that may be used in the delivery of therapy to and diagnosis of ovarian cancer.. .
The University Of North Carolina At Charlotte

Genetic indicator and control system and method utilizing split cas9/crispr domains for transcriptional control in eukaryotic cell lines

While genetic engineering has undergone rapid advancement with the discovery of crispr/cas9, there is room for improvement for genetic circuit control, precision (reducing circuit ‘leakiness’) and delivery into living systems. The claimed invention offers programmable and precise regulation of dcas9 functions in response to multiple molecular signals by using synthetic gene circuits, greatly expanding applications.
Tsinghua University

Antibodies specific for mmp9

The present invention relates to new proteins that bind to mmp9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the mmp9 binding proteins according to the invention are able to neutralize mmp9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers.
Merck Patent Gmbh

Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment

Disclosed herein are methods of treating pancreatic cancer in a human patient by co-administering istiratumab in combination with gemcitabine and nab-paclitaxel, and dosage regimens for the same.. .
Merrimack Pharmaceuticals, Inc.

Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens..
The Regents Of The University Of California

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma.
National Research Council Of Canada

Bcma antibodies and use of same to treat cancer and immunological disorders

The invention provides humanized antibodies that specifically bind to bcma. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting bcma..
Seattle Genetics, Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Prophylaxis of colorectal and gastrointestinal cancer

The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-pg antibodies suitable for use in the methods of the disclosure.
Centre National De La Recherche Scientifique (cnrs)

Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3

Disclosed is an antibody against a secreted form of gpc3 capable of detecting a secreted form of glypican 3 (gpc3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma.
Chugai Seiyaku Kabushiki Kaisha

Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer

Disclosed are chimeric antigen receptors (car) specific to αvβ6 integrin which is uniquely expressed in a wide variety of cancers. Also disclosed are vectors to express the car and methods to use the car to treat patients suffering from cancer.
Immusoft Corporation

Compositions and methods comprising osmium for the treatment of cancers

Compositions and methods comprising osmium are provided. In some embodiments, the osmium compounds comprise a bidentate ligand.
Massachusetts Institute Of Technology

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors.. .
Eli Lilly And Company

Cancer therapeutics

This invention relates to compounds that bind to wild-type cbfβ and inhibit cbfβ binding to runx proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type cbfβ from runx1 in cells, change occupancy of runx1 on target genes, and alter gene expression of runx1 target genes.
University Of Virginia Patent Foundation

Separation of low-abundance cells from fluid using surface acoustic waves

An apparatus for sorting cells from a mixed population of cells using surface acoustic waves is described. Methods for separating cancer cells from a mixed population of cells are provided.
The Penn State Research Foundation

Cancer detection and treatment apparatus

A catheter treatment apparatus comprises an elongate tubular member and an expandable support. The expandable support comprises a radioactive substance to treat cancerous tissue and is configured to expand from a narrow profile for insertion to a wide profile to engage and treat tissue remaining after resection.
Procept Biorobotics Corporation

Bioelectrodynamics modulation method

Disclosed are methods and devices utilizing bioelectrodynamics for the therapeutic treatment of disorders in a subject in need thereof with an electric field or electromagnetic field therapy. The methods and devices provide an inhibitory effect on growth of cancer cells that are exposed to an electromagnetic field generated by a cets unit.

Porous composition filled with an active ingredient

The invention relates to a composition for the release of an active ingredient, comprising a porous matrix, a filled carrier in the matrix and the active ingredient in the carrier. The invention is suitable for the treatment of bone cancers..
I.ceram

Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of non-small cell lung cancer (nsclc) in human subjects.
Purdue Research Foundation

Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof

The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. Sirna or a protein toxin such as ricin toxin a-chain or diphtheria toxin a-chain) and/or a histone-packaged plasmid dna disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the dna into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated dna.
Sandia Corporation

Hematologic cancer treatments

Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., abraxane® nanoparticles) and antibodies.
Mayo Foundation For Medical Education And Research

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Cancer vaccine composition

A cancer vaccine composition for human leukocyte antigen (hla)-a*0206-positive persons, comprising a protein product of the tumor suppressor gene wt1 or a partial peptide thereof.. .
International Institute Of Cancer Immunology, Inc.

Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer..

Method for prophylaxis and/or treatment of erbb1 positive cancers

Provided are compositions and methods for prophylaxis and/or therapy of erbb1-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase d (pepd) proteins.
Health Research, Inc.

Combination methods for immunotherapy

The present invention includes a method of treating prostate cancer in a human subject in need thereof, comprising administering to the subject an effective amount of a composition comprising interleukin-2 (il2), and administering to the subject a cell expressing a chimeric antigen receptor (car) which specifically binds prostate specific membrane antigen (psma), thereby treating prostate cancer in the human subject in need thereof.. .

Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments

Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (gras) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer drugs or devices or other anti-neoplastic agents, treatments, or devices are provided. In some instances, concomitant hyperthermia therapy is employed.
Chemotherapeutics, Llc

Combination therapy for treating cancer

The disclosure relates to combinations comprising inhibitors of human histone methyltransferase dot1l and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.. .
Celgene Corporation

Treatment of cancer

This invention provides medicines and technology for use in treating cancer. The approach is to administer a hypoxia activated prodrug, followed by administration of another chemotherapeutic agent that is not a hypoxia activated prodrug.
Threshold Pharmaceuticals, Inc.

Gold(i) complexes with anticancer properties and methods of use thereof

Monomeric and dimeric gold(i) complexes as anticancer agents. The gold(i) complexes are coordinated to mixed ligands: one phosphine-based ligand that may be monodentate or bidentate and at least one dithiocarbamate-based ligand that is monodentate.
King Fahd University Of Petroleum And Minerals

System and diagnosis and treatment

This invention relates the use of cortisol blockers (glucocorticoid receptor [gr] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.. .
Pop Test Oncology Limited Liability Company





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.1687

file did exist - file did put13255

3 - 1 - 270